Document:

Asset Purchase Agreement, MOMS Pharmacy and H.S. Maiman Rx, Inc.

 Exhibit 10.32 
 ASSET PURCHASE AGREEMENT 
 This ASSET PURCHASE AGREEMENT dated as of March 10, 2006, is by and
between MOMS PHARMACY OF BROOKLYN, INC., a New York corporation (“Buyer”), and H.S. MAIMAN RX, INC., a New York corporation (“Seller”), and SCOTT MAIMAN and NANCY MAIMAN (the “Seller’s Shareholder”). 
 Seller is a licensed New York pharmacy located at 821 Franklin Avenue, Brooklyn, New York. 
 Buyer desires to purchase and Seller desires to sell, transfer and deliver to Buyer Seller’s right title and interest in and to all of its business
and assets including without limitation its fixed assets, inventory, customer lists, prescription files, books and records, files and goodwill, on the terms and conditions set forth in this Agreement. Buyer desires to purchase such business and
assets related to Seller’s HIV/AIDS business (the “HIV/AIDS Business”) and business and assets related to the balance of Seller’s business (the “Non-HIV/AIDS Business”), including without limitation Seller’s
interest in its lease. 
 The parties agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 The terms defined in this Article I, whenever used herein (including the schedules hereto, unless otherwise defined therein), shall have the following meanings: 
 1.1 “Additional Payment” shall have the meaning set forth in Section 2.2(a)(ii) of this Agreement 
 1.2 “Affiliate” shall mean any Person that directly or indirectly controls, is controlled by or is under common control with another
Person. 
 1.3 “Acquired Assets” shall mean all of Seller’s right, title and interest in and to its business, assets
and properties, whether tangible or intangible, and including, without limitation, the Equipment, Inventory, supplies, packaging and shipping materials, the Assumed Contracts, Intellectual Property, tenant improvements, manufacturers warranties,
customer lists, Prescription Files, books and records, files and goodwill, and all other information relating or pertaining to the Acquired Assets. 
 1.4 “Assumed Contracts” shall mean the Contracts listed on Schedule 4.9 of this Agreement that are identified as “Assumed Contracts”. 
 1.5 “Business Day” shall mean any day other than a Saturday, Sunday or other day on which banks are closed or are authorized to be closed in New York, New York. 

 1.6 “Buyer Claimant” shall have the meaning set forth in Section 8.2 of this
Agreement. 
 1.7 “Closing” shall mean the closing of the purchase and sale of the Acquired Assets, as contemplated by this
Agreement. 
 1.8 “Closing Date” shall have the meaning set forth in Section 3.1 of this Agreement. 
 1.9 “Code” shall mean the Internal Revenue Code of 1986, as amended. 
 1.10 “Contract” shall have the meaning set forth in Section 4.3 of this Agreement. 
 1.11 “Employee Benefit Plan” means any “employee benefit plan” within the meaning of Section 3(3) of ERISA, and any other
bonus, profit sharing, compensation, pension, severance, deferred compensation, fringe benefit, insurance, welfare, medical, post-retirement health or welfare benefit, medical reimbursement, health, life, stock option, stock purchase, tuition
refund, service award, company car, scholarship, relocation, disability, accident, sick pay, sick leave, vacation, termination, individual employment, executive compensation, incentive, bonus, commission, payroll practices, retention or other plan,
agreement, policy, trust fund or arrangement, whether written or unwritten, and whether maintained, sponsored or contributed to by Seller or any entity that would be deemed a “single employer” with Seller under Section 414(b), (c),
(m) or (o) of the Code or Section 4001(a)(14) of ERISA (an “ERISA Affiliate”) on behalf of any of the current, former or retired employees of Seller or its beneficiaries or with respect to which Seller or any ERISA Affiliate
has or has had any obligation on behalf of any such employee or beneficiary. 
 1.12 “Encumbrance” shall mean any lien,
charge, encumbrance, option, right of first refusal, security interest, easement, obligation or claim or other third party right of any kind. 
 1.13 “Environment” shall mean any surface or subsurface physical medium or natural resource, including, air, land, soil, surface waters, ground waters, stream and river sediments, and biota. 
 1.14 “Environmental Laws” shall mean any federal, state, local or foreign law, rule, regulation, ordinance, code, order or judgment
(including the common law and any judicial or administrative interpretations, guidances, directives or opinions) relating to the injury to, or the pollution or protection of human health and safety or the Environment. 
 1.15 “Environmental Liabilities” shall mean any claims, judgments, damages (including punitive damages), losses, penalties, fines,
liabilities, encumbrances, liens, violations, costs and expenses (including attorneys and consultants fees) of investigation, remediation or defense of any matter relating to human health, safety or the Environment of whatever kind or nature by any
party, entity or authority, (a) which are incurred as a result of (i) the existence of Hazardous Substances in, on, under, at or emanating from any real property presently or formerly owned or operated by Seller or any of its Affiliates,
(ii) the offsite transportation, treatment, storage or disposal of Hazardous Substances generated by Seller or any of its Affiliates, or (iii) the violation of any Environmental Laws or (b) which arise under the Environmental Laws.

  

 2 

 1.16 “Equipment” shall mean all items of machinery, equipment, computers, tools, parts,
furniture and fixtures set forth on Schedule 4.6 and all other items of machinery, equipment, computers, tools, parts, furniture and fixtures owned by Seller. 
 1.17 “ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended, and the regulations thereunder. 
 1.18 “ERISA Affiliate” shall have the meaning set forth in the definition of “Employee Benefit Plan”. 
 1.19 “Excluded Liabilities” shall have the meaning set forth in Section 2.1(c) of this Agreement. 
 1.20 “Financial Statements” shall mean (a) the financial statements of the Seller as of December 31, 2003 and 2004, and for each of the fiscal years then ended, and (b) the revenue
analysis of the Seller for the fiscal year ended December 31, 2005. 
 1.21 “GAAP” shall mean generally accepted
accounting principles. 
 1.22 “Hazardous Discharge” shall mean any releasing, spilling, leaking, pumping, pouring,
emitting, emptying, discharging, injecting, escaping, leaching, migrating, disposing or dumping (including the movement of any material through or in air, soil, surface or groundwater) of Hazardous Substances, whether on, off, under or from any real
property owned, operated, leased or used at any time by Seller or its predecessors. 
 1.23 “Hazardous Substances” shall
mean petroleum, petroleum products, petroleum-derived substances, radioactive materials, hazardous wastes, polychlorinated biphenyls, lead based paint, urea formaldehyde, asbestos or any materials containing asbestos, and any materials, wastes or
substances regulated or defined as or included in the definition of “hazardous substances,” “hazardous materials,” “hazardous constituents,” “toxic substances,” “pollutants,” “contaminants”
or any similar denomination intended to classify substances by reason of toxicity, carcinogenicity, ignitability, corrosivity or reactivity under any Environmental Laws. 
 1.24 “Indemnitee” and “Indemnitor” shall have the meanings set forth in Section 8.4(a) of this Agreement. 
 1.25 “Initial Payment” shall have the meaning set forth in Section 2.2(a)(i) of this Agreement. 
 1.26 “Intellectual Property” means (a) all United States and foreign patents and pending patent applications, trademarks, service
marks and trade names, including, without limitation, the marks and patents described on Schedule 4.8 of this Agreement, and copyrights, and registrations and pending applications, computer programs and software, research and development, know-how,
inventions and other proprietary processes and information of any kind, and all software necessary or desirable to run Equipment, all as set forth on Schedule 4.8 of this Agreement; (b) all copies and tangible embodiments of the foregoing; and
(c) the right to sue for past and future misappropriation or infringement of any of the foregoing 
  

 3 

 1.27 “Inventory” means all items of Seller’s inventory, including inventory related
to the HIV/AIDS Business, provided that, with respect to inventory related to the HIV/AIDS Business, an item shall be considered “Inventory” only if Seller has provided to Buyer the following information for such item prior to or within
ten (10) days following the Closing Date: (a) the proprietary and established name of the item; (b) dosage; (c) container size; (d) number of containers; (e) the item’s lot or control number(s); (f) the
business name and address of all parties to each prior transaction involving the item, starting with the manufacturer; and (g) the date of each previous transaction. 
 1.28 “Inventory Payment” shall have the meaning given such term in Section 2.2(b) of this Agreement. 
 1.29 “IRS” shall mean the Internal Revenue Service. 
 1.30 “Licenses and
Permits” shall have the meaning set forth in Section 4.14 of this Agreement. 
 1.31 “Losses” shall have the
meaning set forth in Section 8.2 of this Agreement. 
 1.32 “Material Adverse Effect” shall mean any material adverse
effect, individually or in the aggregate, on the condition (financial or otherwise), business, assets, operations or prospects of Seller or the Acquired Assets. 
 1.33 “Payment Program” shall have the meaning set forth in Section 4.19 of this Agreement. 
 1.34 “Person” shall mean any natural person, corporation, professional corporation, limited or limited liability partnership, general partnership, joint venture, association, joint-stock company, limited liability company,
company, trust, bank, trust company, land trust, business trust or other organization, whether or not a legal entity, and any governmental unit or agency or political subdivision thereof. 
 1.35 “Prescription Files” shall mean all prescription files owned or used by Seller that are associated with Seller’s business, and
all customer data and information derived from customer purchases from Seller. 
 1.36 “Purchase Price” shall have the
meaning set forth in Section 2.2(b) of this Agreement. 
 1.37 “Real Property” shall mean the real property and
interests in real property described on Schedule 4.17 leased by Seller and the plants, buildings, structures, storage tanks, erections and improvements of all kinds made to, located on or forming a part of the real property and interests in real
property (including, without limitation, all fixtures), together with all easements, rights-of-way, appurtenances and tenements to, on or otherwise beneficial to the use of such real property or interests in real property 
 1.38 “Related Party” shall have the meaning set forth in Section 4.13 of this Agreement. 
  

 4 

 1.39 “Seller Claimant” shall have the meaning set forth in Section 8.3 of this
Agreement. 
 1.40 “Taxes” (or “Tax” where the context requires) shall mean all federal, state, local, foreign or
other taxes, duties, or similar charges (including, without limitation, income (whether net or gross), profits, premium, estimated, excise, sales, use, environmental (including taxes under Code Section 59A), occupancy, franchise, license, value
added stamp, windfall profits, social security, gross receipts, franchise, ad valorem, severance, capital levy, production, transfer, gains, withholding, occupation, employment and payroll related and property taxes, alternative or add-on, minimum
or estimated, import and export duties and other governmental charges and assessments) imposed by any taxing or governmental authority on or payable by Seller or any other party with respect to the income, operations, products, assets or properties
of Seller, whether attributable to statutory or nonstatutory rules and whether or not measured in whole or in part by net income, and including interest, additions to tax or interest, and penalties with respect thereto, and including expenses
associated with contesting any proposed adjustment related to any of the foregoing. 
 ARTICLE II 
 SALE AND PURCHASE OF THE ACQUIRED ASSETS 
 2.1 Purchase of the Acquired Assets. 
 (a) Upon the terms and subject to the conditions hereof, and upon the basis of
the agreements, representations and warranties contained in, and the schedules to, this Agreement, at the Closing, Seller shall sell, transfer, assign, convey and deliver to Buyer, and Buyer shall purchase and acquire from Seller, all of the
Acquired Assets, in each case free and clear of Encumbrances of any kind. 
 (b) Notwithstanding anything contained in this Agreement,
Seller shall not sell, transfer, assign, convey or deliver to Buyer, and Buyer shall not purchase or acquire from Seller, any of Seller’s cash or accounts receivable, and any other assets of Seller listed on Schedule 2.1. If at any time Buyer
receives any payment in respect of accounts receivable of Seller, Buyer shall keep such payment segregated from its other funds, and shall promptly forward to Seller or pay to Seller an amount equal to such payment so received. 
 (c) Buyer shall not be required to assume, pay, fulfill, perform or otherwise discharge any liabilities or obligations of Seller, including of
Seller’s business, of any kind whatsoever (the “Excluded Liabilities”), and Seller shall pay, fulfill, perform and discharge such Excluded Liabilities when due. The Excluded Liabilities include, without limitation: 
 (i) Legal, accounting, brokerage, finder’s fees, Taxes or other expenses incurred by Seller or any Affiliate, including, without limitation, in
connection with this Agreement or the consummation of the transactions contemplated hereby; 
 (ii) Any intercompany debt or other liability
or obligation of any nature between Seller and any past or present Related Party of Seller; 
  

 5 

 (iii) Liabilities or obligations incurred by Seller or any Affiliate of Seller after the Closing;

 (iv) Except as to any claim that would be covered by an indemnification in favor of Seller, any obligation or liability relating to any
litigation or any claim arising out of any dispute, the elements of which occurred prior to the Closing, or any litigation or other claim against Seller, whether or not listed on any schedule hereto and regardless of whether accruing prior to or
subsequent to the Closing; 
 (v) Any liability for any Taxes accrued to or incurred by Seller or any Affiliate of Seller or relating to
operations, products or assets of Seller or any Affiliate of Seller or arising as a consequence of the transactions contemplated hereby; 
 (vi) Any liability or costs (including, without limitation, costs of remediation) arising out of or relating to a Hazardous Discharge or the release, discharge or disposal of any solid wastes or the handling, storage, use, transportation or
disposal of any of the foregoing, as these terms are defined by the Environmental Laws in, on, under or from facilities of Seller at any time prior to the Closing, regardless of whether such liability or costs arise before or after Closing and
whether or not in breach of any representation or warranty under this Agreement; 
 (vii) Any liability or obligation to employees,
government agencies or other third parties in connection with any option plan, pension plan, other ERISA plan or other Employee Benefit Plan, and any health, dental or life insurance benefits, whether or not insured and whether or not disclosed on
any schedule hereto; 
 (viii) Any liability or obligation under any contract or commitment which is not an Assumed Contract, and any
liability or obligation which relates to any default in respect of such contract or other commitment or obligation of Seller; 
 (ix) Any
liability or obligation to employees in the nature of accrued payroll, vacation, holiday or sick pay, worker’s compensation relating to the period prior to the Closing, whether or not listed on any schedule hereto and regardless of whether
accruing prior or subsequent to the Closing; 
 (x) Any trade debt, accounts payable, notes payable and bank debts; or 
 (xi) Any other liability, debt or obligation of Seller or any of its Shareholders. 
 2.2 Purchase Price. 
 (a) In
consideration for the Acquired Assets (other than the Inventory), Buyer shall pay to Seller an amount in cash equal to Five Million Two Hundred Fifty Thousand Dollars ($5,250,000), payable as follow: 
 (i) At the Closing, Buyer shall pay to Seller and amount in cash equal to Four Million Seven Hundred Twenty-Five Thousand Dollars ($4,725,000) (the
“Initial 

  

 6 

 
Payment”). One Million Dollars ($1,000,000) of the Initial Payment shall be held by Seller’s counsel in an escrow account of Seller’s counsel,
and shall be used solely for the purpose of discharging Seller’s secured indebtedness to Bellco Drug Corp. Kinray, Inc. and Commerce Bank, N.A., which indebtedness shall be discharged in full promptly after the Closing. To the extent that any
sums remain in such escrow account after discharge in full of such indebtedness, such sums may be released to Seller; and 
 (ii) In
addition, on May 13, 2006, Buyer shall pay to Seller an amount equal to Five Hundred Twenty-Five Thousand Dollars ($525,000) (the “Additional Payment”) if, and only if, Seller and Seller’s management, including Scott Maiman, have
during the two (2) month period from the Closing Date through May 13, 2006 provided during normal business hours such reasonable assistance to Buyer as Buyer from time to time has requested to transition the business of Seller and the
Acquired Assets to Buyer, which assistance may be provided by telephone in such cases that physical presence is not necessary to provide such assistance; and 
 (b) On March 31, 2006, in consideration for the Inventory, Buyer shall pay to Seller an amount equal to the lesser of (x) the Seller’s wholesale acquisition cost of the Inventory (as calculated by Buyer
based on documentation provided by Seller to Buyer) and (y) the Buyer’s wholesale acquisition cost of the types of items included in the Inventory (but not less than two percent (2%) less than Seller’s wholesale acquisition of
such items, calculated on an item-by-item basis), in each case only to the extent that such Inventory conforms to the representation contained in Section 4.6 and Buyer otherwise in its sole discretion elects by that date, by notice to Seller,
to purchase and acquire such Inventory from Seller (the “Inventory Payment” and, collectively with the Initial Payment and the Additional Payment, the “Purchase Price”). The inventory of Seller shall occur on March 12, 2006,
and the amount of the Inventory Payment shall be as mutually agreed by Buyer and Seller based upon the valuation principles set forth above. To the extent that the amount of the Inventory Payment is not agreed to by March 31, 2006, Buyer shall
pay to Seller the amount of the Inventory Payment to the extent not in dispute on that date, and the parties shall continue to work in good faith to resolve any remaining differences. 
 2.3 Allocation of Purchase Price. The Purchase Price for the Acquired Assets shall be allocated for federal, state, local and foreign tax purposes
by each party among the Acquired Assets as mutually determined by Seller and Buyer, in compliance with applicable laws and generally accepted accounting principles. For all pertinent tax purposes, each party hereto shall report the purchase and sale
provided for, and with the characterization given these transactions in this Agreement, to taxing authorities on a basis consistent with such allocation, and each party agrees not to take a position inconsistent with such allocation. After the
Closing, Seller and Buyer each shall timely file form 8594 with the IRS detailing this allocation. In the event that Buyer determines, subject to Seller’s reasonable approval, that any adjustments to such allocation are necessary, Seller shall
make such modifications as are necessary, reporting the same on Seller’s form 8594 (if required) or any tax report or return filed or to be filed by Seller in order to conform to Buyer’s allocation as adjusted. 
 2.4 Nonassignable Contracts. To the extent that the assignment of the Assumed Contracts shall require the consent of any other Person, this
Agreement shall not constitute a contract to assign the same if an attempted assignment would constitute a breach thereof. Seller shall use all reasonable efforts, and Buyer shall cooperate where appropriate, to obtain any consent necessary to any
such assignment where such consent is requested by Buyer. 
  

 7 

 ARTICLE III 
 CLOSING 
 3.1 The Closing. Subject to the terms and conditions of this Agreement, the
Closing shall occur on March 13, 2006 (the “Closing Date”), at the offices of Buyer’s counsel, Nixon Peabody LLP, 990 Stewart Avenue, Garden City, New York. 
 3.2 Obligations of Seller. At the Closing, Seller shall deliver to Buyer the following: 
 (a) A bill of sale, in customary form, duly executed by Seller. 
 (b) A Limited Power of Attorney for Use of Pharmacy Licenses, Medicaid Number, DEA Registration Numbers and DEA Order Forms. 
 (c) A grant of permission to Buyer from Seller to utilize Seller’s National Counsel for Prescription Drug Programs number. 
 (d) A copy of the agreement between Seller and/or one or both of Seller’s Shareholders and Josette Toussaint, which agreement shall not be modified or amended, or any of its provisions waived or released, without
Buyer’s consent. 
 (e) A legal opinion of counsel to Seller and Seller’s Shareholders, covering the matters set forth in
Exhibit A. 
 (f) Copies of the resolutions of the Board of Directors and shareholders of Seller certified by the secretary or
assistant secretary of Seller, which resolutions shall approve and authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby. 
 (g) All consents to the assignment to Buyer of each of the Acquired Assets, including without limitation all consents to the assignment to Buyer of
Seller’s lease, provided that if the consent to the assignment to Buyer of Seller’s lease is not obtained prior to the Closing, the parties shall continue to use their commercially reasonable best efforts to obtain such consent. To the
extent that Seller’s security deposit under its lease is not returned by the landlord thereunder to Seller, Buyer shall at or immediately following the Closing reimburse Seller therefor, and thereafter shall be entitled to the security deposit
in accordance with the terms and conditions of the lease as assignee thereunder. 
 (h) Such other instruments of assignment and conveyance
as may be necessary or appropriate to fully and effectively transfer to Buyer the Acquired Assets. 
 (i) All of the other documents and
instruments required to be delivered by Seller. 
  

 8 

 3.3 Obligations of Buyer. At the Closing, Buyer shall deliver to Seller the following: 

(a) The Initial Payment. 
 (b) Copies of
the resolutions of the Board of Directors of Buyer certified by the secretary or assistant secretary of Seller, which resolutions shall approve and authorize the execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby. 
 (c) All of the other documents and instruments required to be delivered by Buyer. 
 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES
REGARDING SELLER AND SELLER’S BUSINESS 
 Seller and Seller’s Shareholders hereby represent and warrant to Buyer, as of the
date hereof and as of the Closing, as follows: 
 4.1 Organization and Qualification. Seller is a corporation duly organized, validly
existing and in good standing under the laws of the State of New York, with full corporate power and authority to own, lease and operate its properties and assets and to conduct its business as it is now being conducted. Seller has no Affiliates,
subsidiaries or equity interest in any other Person. Seller is duly qualified and in good standing as a foreign corporation and has all requisite corporate power and authority to do business in the jurisdictions set forth on Schedule 4.1, which
jurisdictions are the only jurisdictions wherein the character of the properties owned or leased or the nature of activities conducted by Seller make such qualification necessary. Seller’s Shareholders own all the issued and outstanding capital
stock of Seller. 
 4.2 Authority. Seller has all requisite power and authority to execute and deliver this Agreement and all
documents, certificates, agreements, instruments and writings related hereto to which it is a party and to perform, carry out and consummate the transactions contemplated hereby and thereby. The execution, delivery and performance of this Agreement
have been duly authorized by all necessary corporate action on the part of Seller. This Agreement has been duly and validly executed by Seller and constitutes the legal, valid and binding obligations of Seller, enforceable against Seller in
accordance with its terms. 
 4.3 No Breach. Except as set forth on Schedule 4.3, neither the execution and delivery of this Agreement
by Seller nor the consummation of the transactions contemplated hereby will: (a) violate any provision of the Certificate of Incorporation or Bylaws of Seller; (b) conflict with, result in a breach of or constitute a default (or an event
which, with or without notice, lapse of time or both, would constitute a default) under any leases, agreements, instruments, arrangements, contracts, commitments or understandings, written or oral, to which Seller is a party or by which Seller or
any of the Acquired Assets is bound (collectively, the “Contracts”) listed on Schedule 4.9; (c) result in the creation of, or give any party the right to create, any Encumbrance upon any of the Acquired Assets; (d) conflict with,
violate, result in a breach of or constitute a 
  

 9 

 default under any judgment, decree, order or process of any court or governmental authority; (e) conflict with or
violate any statute, law or regulation applicable to Seller or any of the Acquired Assets; or (f) require Seller to obtain any authorization, consent, approval or waiver from, or to make any filing with, any governmental or regulatory
authority, or other third party. 
 4.4 Financial Statements and Sales Information. Prior to the date hereof, Seller has delivered to
Buyer the Financial Statements, which are attached hereto as Schedule 4.4. The Financial Statements: (a) were prepared from the books and records prepared from Seller’s compilation statements, which books and records have been maintained
in accordance with all legal and accounting requirements and completely and accurately reflect all financial transactions of Seller, including, without limitation, the accounts receivable, accounts payable and revenue of Seller for the periods
covered by and as at the dates of the Financial Statements; (b) were prepared in accordance with GAAP consistently applied; and (c) are true and correct, and present fairly the financial condition of Seller and the results of its
operations for the periods covered by, and as at the dates of, each of the Financial Statements. The Financial Statements do not contain any material items of special or non-recurring income or other income not earned in the ordinary course of
business except as expressly specified therein. All liabilities (whether accrued, unmatured, contingent or otherwise, and whether due or to become due) of Seller are set forth or adequately reserved against on the face of the most recent Financial
Statements, except for liabilities incurred since the date thereof in the ordinary course of business as theretofore conducted, which liabilities are not, individually or in the aggregate, materially adverse to the condition (financial or
otherwise), business, assets, operations or prospects of Seller. Seller is neither aware nor ought reasonably to be aware of any basis for the assertion against Seller of any materially adverse liability or loss contingency. Prior to the date
hereof, Seller has provided Buyer with sales information, by patient, for its past three fiscal years. The books and records of Seller are accurate and complete and have been maintained in accordance with good business practices. 
 4.5 Absence of Certain Changes or Events. Since December 31, 2004: Seller’s business has been conducted and the Acquired Assets have
been acquired and operated only in the ordinary and usual course consistent with past practice; neither Seller’s business nor the Acquired Assets have suffered any event or condition that has had a Material Adverse Effect; and Seller is not
aware of any event or condition that has occurred or would reasonably be expected to occur that could result in a Material Adverse Effect. 
 4.6 Acquired Assets. Seller has good and freely transferable title to all of the Acquired Assets, free and clear of all Encumbrances, and has the complete and unrestricted power and right to sell and transfer the Assets to Buyer in
accordance with the terms hereof. Schedule 4.6 sets forth a complete and accurate list of all items of Equipment. Each piece of Equipment is and will when delivered be adequate for the uses to which it is being put, is and will when delivered be in
good order and working condition, ordinary wear and tear excepted, and have no material defects, and no condition exists or will when such Equipment is delivered exist which interferes with the value thereof or the use thereof. Seller has maintained
the Equipment in accordance with good business practices. The Acquired Assets constitute all of the properties and assets used by Seller in connection with the operation of Seller’s business, and include all of the properties and assets
necessary to operate Seller’s business as it has been operated. All items included in the Inventory consist of a quality and quantity usable and saleable in the ordinary course of business of Seller, and are not damaged, below-standard quality
or, in the reasonable belief of Seller and the Shareholders, in excessive quantities. 
  

 10 

 4.7 Real Property. Seller does not own any real property. Schedule 4.7 sets forth an accurate and
complete list of all leases of Real Property used by Seller in connection with Seller’s business. Seller has peaceful possession of the Real Property and has no other interest in real property in connection with Seller’s business. The Real
Property is and will when delivered be in good order and working condition, ordinary wear and tear excepted, and have no material defects. No condition exists or will when such property is delivered exist which interferes with the value thereof or
the use thereof in the manner used by or for Seller’s business prior to the Closing Date. Seller has maintained the Real Property in accordance with good business practices. 
 4.8 Intellectual Property. Seller owns or licenses all the Intellectual Property, including, without limitation, all patents, trademarks, service
marks, trade names and copyrights, in each case registered or unregistered, inventions, know-how, trade secrets and other intellectual property rights used in the Seller’s business as presently conducted. Schedule 4.8 contains a list of all
Intellectual Property owned and used by Seller and any Intellectual Property which is licensed for use by others. No Intellectual Property infringes any rights owned or held by any other person. There is no pending or, to the knowledge of Seller,
threatened claim or litigation against Seller or Seller’s business contesting its right exclusively to use any Intellectual Property. To the knowledge of Seller, no person is infringing the rights of Seller or Seller’s business in any
Intellectual Property. No product or service sold or provided by Seller’s business violates or infringes any intellectual property right owned or held by any other person. To the knowledge of Seller, all Intellectual Property used in the
Seller’s business as presently conducted is valid, enforceable and subsisting, and all application, issuance, renewal, maintenance and other payments that are or have become due with respect thereto have been timely paid and all assignments,
certificates and other instruments necessary to perfect and record Seller’s rights thereto have been timely filed with the relevant governmental offices. 
 4.9 Contracts and Commitments. Schedule 4.9 is a list of all Contracts that are material to the business or operations of Seller. Seller is not in breach or default, nor is there any basis for any valid claim
of breach or default by Seller, under any Contract. The Contracts are valid and in full force and effect and, assuming the obtaining of any consents to the assignment thereof, consummation of the transactions contemplated by this Agreement will not
cause any Contract to cease to be valid and in full force and effect. Accurate and complete copies of the Contracts listed on Schedule 4.9, including all amendments thereto, have been or will promptly after the Closing be delivered to Buyer to the
extent in Seller’s possession. 
 4.10 Litigation, Etc. Except as set forth on Schedule 4.10, there has not been in the five
years prior to the date hereof, nor is there currently, any claim, action, suit, inquiry, proceeding or, to the best of Seller’s knowledge, investigation of any kind or nature whatsoever, by or before any court or governmental or other
regulatory or administrative agency, commission or tribunal brought, asserted or initiated by Seller, or pending or, to the best of Seller’s knowledge, threatened against or involving Seller. To the best of Seller’s knowledge, there is no
valid basis for any such claim, action, suit, inquiry, proceeding or investigation. Seller is not subject to any judgment, order or decree. 
  

 11 

 4.11 Compliance with Law. Seller is and has been conducting its business, marketing and selling
its services and/or products, and owning and operating all of its assets, in compliance in all material respects with all applicable laws, rules, regulations, orders, codes, ordinances, authorizations, judgments and decrees, of all federal, state,
local, foreign or other governmental or regulatory authorities. Seller and each of its employees or agents providing services at the pharmacy, as applicable, (a) hold all permits, licenses, registrations, franchises, certificates, concessions
and other governmental approvals and authorizations (the “Licenses and Permits”) required for the operation of Seller’s business, including, without limitation, all Licenses and Permits required by federal, state and local law and all
applicable regulatory agencies, and (b) are in compliance in all material respects with all applicable laws, regulations and agreements, including without limitation the Health Insurance Portability and Accountability Act of 1996 as it relates
to the maintenance of customer and patient lists and records. All such Licenses and Permits are in full force and effect and Seller is not in default in any respect with respect to any such Licenses and Permits. No notice from any authority with
respect to the revocation, termination, suspension or limitation of any such Licenses and Permits has been issued or given, nor is Seller aware of the proposed or threatened issuance of any such notice. 
 4.12 Finders. Neither Seller, nor any of its Affiliates, nor any of Seller’s directors or officers, has taken any action that, directly or
indirectly, would obligate Buyer or any of its Affiliates to anyone acting as broker, finder, financial advisor or in any similar capacity in connection with this Agreement or any of the transactions contemplated hereby. 
 4.13 Related Party Transactions; Intercompany Accounts. Except as set forth on Schedule 4.13, there are no Contracts between Seller, on one hand,
and any shareholder, director, officer, employee, consultant or Affiliate of Seller (each, a “Related Party”), on the other, related to Seller’s business. Set forth on Schedule 4.13 is a true and complete list of each transaction
during the prior 18 months between Seller, on one hand, and any Related Party, on the other, related to Seller’s business. Except for compensation for services rendered, no amounts are owed by or to Seller to or by any Related Party, related to
Seller’s business. 
 4.14 Tax Matters. All Taxes that are due or payable by Seller, whether or not disputed by Seller, have been paid
in full. All tax returns to be filed in connection with Taxes have been accurately prepared and duly and timely filed. Attached as Schedule 4.14 are true, complete and accurate copies of Seller’s Federal and state income tax returns for 2002,
2003 and 2004. 
 4.15 Improper Payments. Neither Seller, nor any of Seller’s officers and employees nor, to the best of
Seller’s knowledge, Seller’s agents have made any illegal or improper payments to, or provided any illegal or improper benefit or inducement for, any governmental official, supplier, customer or other person, in an attempt to influence any
such person to take or to refrain from taking any action relating to Seller’s business. 
 4.16 Payment Programs. Neither Seller,
nor any of its officers or employees, nor, to the best knowledge of Seller, agents has received written notice that it is subject to any restriction or limitation on the receipt of payment under the Medicare or Medicaid programs, any other federally
funded health care program or any other third party payor (collectively, the “Payment Programs”). Seller has valid and current provider agreements with the Payment Programs. Seller is in compliance in all material respects with the
conditions of participation for 
  

 12 

 the Payment Programs. Neither Seller, nor any of Seller’s officers or employees, nor, to the best knowledge of
Seller, agents has received written notice that a Payment Program has requested or threatened any recoupment, refund or set-off from Seller, or imposed any fine, penalty or other sanction on Seller, nor has Seller been excluded from participation in
a payment program. Seller has not submitted to a Payment Program any false or fraudulent claim for payment, nor has Seller at any time violated in any material respect any condition for participation, or any published rule, regulation, policy or
standard of a Payment Program. 
 4.17 Fraud and Abuse. Neither Seller, nor any of Seller’s officers, employees or agents,
has engaged in any activities that are prohibited under Federal Medicare and Medicaid statutes, 42 U.S.C. §§ 1320a-7, 1320a-7a, 1320a-7b or the Federal False Claims Act, 31 U.S.C. § 3729 et seq., the regulations promulgated pursuant
to such statutes, or any related state or local statutes or regulations. 
 4.18 Physician Self-Referrals. Seller’s operations
are in compliance in all material respects with and do not otherwise violate the Federal Medicare and Medicaid statutes regarding physician self-referrals, 42 U.S.C. §§ 1395nn and 1396b(s), the regulations promulgated pursuant to such
statutes, or any related state or local statutes or regulations. Neither Seller, nor any of Seller’s officers, employees or agents, has engaged in any activities that may violate such statutes or regulations. 
 4.19 Controlled Substances. Seller has not engaged in any activities which are prohibited under the Federal Controlled Substances Act, 21 U.S.C.
§ 801 et seq., or the regulations promulgated pursuant to such statute or any related state or local statutes or regulations concerning the dispensing and sale of controlled substances. 
 4.20 Customers and Suppliers. Brookdale Hospital is Seller’s largest customer in terms of referrals of customers. Seller’s largest
suppliers in order of dollar volume of purchases are HD Smith, Bellco Drug Corp. and Kinray, Inc. There has not been any adverse change and there are no facts known to Seller which may reasonably be expected to indicate that any adverse change may
occur in the business relationship of Seller or, after the Closing, Buyer with any supplier or referral source listed above. 
 4.21
Insurance. Schedule 4.21 contains a complete and correct list of all policies of insurance of any kind or nature covering Seller, including, without limitation, policies of life, fire, theft, casualty, product liability, workmen’s
compensation, business interruption, employee fidelity and other casualty and liability insurance, indicating the type of coverage, name of insured, the insurer, the premium, the expiration date of each policy and the amount of coverage. All such
policies (a) are with insurance companies reasonably believed by Seller to be financially sound and reputable and are in full force and effect; (b) are sufficient for compliance with all requirements of law and of all applicable
agreements; (c) are valid, outstanding and enforceable policies; and (d) provide full insurance coverage for the assets and operations of Seller for all risks normally insured against by persons carrying on the same business as Seller.
Complete and correct copies of such policies have been furnished to Buyer. 
  

 13 

 4.22 Employee Benefit Plans; Employees. 
 (a) Schedule 4.22 hereto sets forth a true and complete list of each Employee Benefit Plan. 
 (b) Each of the Employee Benefit Plans is and has been in compliance with all applicable laws, including without limitation ERISA and the Code in all
material respects; each of the Employee Benefit Plans intended to be “qualified” within the meaning of Section 401(a) of the Code is so qualified and has received a determination letter from the Internal Revenue Service pursuant to
Revenue Procedure 93-39 to the effect that such Employee Benefit Plan is qualified under Section 401(a) of the Code; no Employee Benefit Plan has or is expected to have an accumulated or waived funding deficiency within the meaning of
Section 412 of the Code; neither Seller nor any ERISA Affiliate has incurred or is expected to incur, directly or indirectly, any liability (including any contingent liability) to or on account of a Employee Benefit Plan pursuant to Title IV of
ERISA; no proceedings have been instituted to terminate any Employee Benefit Plan that is subject to Title IV of ERISA; no “reportable event,” as such term is defined in Section 4043(b) of ERISA, has occurred or is expected to occur
with respect to any Employee Benefit Plan; and no condition exists that presents a risk to Seller or any ERISA Affiliate of incurring a liability to or on account of an Employee Benefit Plan pursuant to Title IV of ERISA. 
 (c) The current value of the assets of each of the Employee Benefit Plans that are subject to Title IV of ERISA, based upon the actuarial assumptions
(to the extent reasonable) presently used by the Employee Benefit Plans, exceeds the present value of the accrued benefits under each such Employee Benefit Plan calculated as the projected benefit obligation using the methodology under Financial
Accounting Standards Board Statement No. 87; no Employee Benefit Plan is a multiemployer plan (within the meaning of Sections 3(37) or 4001(a)(3) of ERISA or Section 414(f) of the Code (“Multiemployer Plan”) and no Employee
Benefit Plan is a multiple employer plan subject to Sections 4063 and 4064 of ERISA or as defined in Section 413 of the Code (“Multiple Employer Plan”); and all contributions or other amounts payable by Seller as of the Closing with
respect to each Employee Benefit Plan in respect of current or prior plan years have been paid. Neither Seller nor any ERISA Affiliate is or was obligated to contribute to any Multiemployer Plan or Multiple Employer Plan. There are no pending,
threatened or, to the best knowledge of Seller, anticipated claims (other than routine claims for benefits) by, on behalf of or against any of the Employee Benefit Plans or any trusts related thereto. 
 (d) No Employee Benefit Plan provides death or medical benefits (whether or not insured), with respect to current or former employees of Seller or any
ERISA Affiliate beyond their retirement or other termination of service other than (i) coverage mandated by applicable law or (ii) death benefits under any “employee pension plan” (as that term is defined in Section 3(2) of
ERISA) that is qualified under Section 401(a) of the Code. 
 4.23 Disclosure. No representation, warranty or other statement by
Seller herein or made in writing in connection herewith contains or will contain an untrue statement of a material fact, or omits or will omit to state a material fact necessary to make the statements contained herein or therein not misleading.

  

 14 

 ARTICLE V 
 REPRESENTATIONS AND WARRANTIES REGARDING BUYER 
 Buyer hereby represents and warrants to Seller as
follows: 
 5.1 Organization and Qualification. Buyer is a corporation duly organized, validly existing and in good standing under the
laws of the State of New York, with full corporate power and authority to own, lease and operate its properties and assets and to conduct its business as it is now being conducted. 
 5.2 Authority. Buyer has all requisite power and authority to execute and deliver this Agreement and to perform, carry out and consummate the
transactions contemplated hereby. The execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on the part of Buyer. This Agreement constitutes the legal, valid and binding obligations of
Buyer, enforceable against Buyer in accordance with its terms. 
 5.3 No Breach. Neither the execution and delivery of this
Agreement by Buyer nor the consummation of the transactions contemplated herein will: (a) violate any provision of the Certificate of Incorporation or Bylaws of Buyer; (b) conflict with, result in a breach of or constitute a default (or an
event which, with or without notice, lapse of time or both, would constitute a default) under, or give any third party the right to terminate or modify, any material agreement or other instrument to which Buyer is a party or by which it or any of
its assets is bound; (c) conflict with, violate, result in a breach of or constitute a default under any judgment, decree, order or process of any court or governmental authority; (d) conflict with or violate any material statute, law or
regulation applicable to the business of Buyer; or (e) require Buyer to obtain any authorization, consent, approval or waiver from, or to make any filing with, any governmental or regulatory authority. 
 5.4 Finders. Neither Buyer, nor any of its Affiliates, nor any of their respective directors or officers, has taken any action
that, directly or indirectly, would obligate Seller or any of its Affiliates to anyone acting as a broker, finder, financial advisor or in any similar capacity in connection with this Agreement or any of the transactions contemplated hereby.

 ARTICLE VI 
 COVENANTS

 6.1 Obtaining Consents. Buyer and Seller shall use all reasonable efforts to obtain all consents, approvals and waivers from,
and give all notices to, and make all declarations, filings and registrations with, any governmental and regulatory agencies and other third parties that are required to consummate or are otherwise related to the transactions contemplated hereby.
Buyer and Seller shall coordinate and cooperate with one another and supply such assistance as may be reasonably requested by each in connection with the foregoing. 
 6.2 Transfer and Retention of Records. Except as may be required for tax purposes or other regulatory purposes, neither Seller, nor any of its respective successors and assigns, will retain any document,
databases or other media embodying any confidential or proprietary 
  

 15 

 information relating to Seller’s business or use, publish or disclose to any third person any such confidential or
proprietary information relating to Seller’s business; provided, however, that Seller shall be entitled to retain copies of any of the foregoing (and have access to the same after the Closing) to the extent necessary in connection
with prosecuting or defending any matter not assumed by Buyer. Seller shall take all actions requested by Buyer to transfer records relating to Seller’s business to Buyer, which may include making duplicate copies of any records retained by
Seller in the form of papers or computer media. 
 6.3 Employee Matters. Buyer shall not assume or be responsible in any way for
the obligations, liabilities or responsibilities (a) of any Employee Benefit Plan of Seller, (b) of Seller, any Affiliate of Seller or any fiduciary under, arising from, or with respect to any Employee Benefit Plan of Seller or (c) to
any of Seller’s officers, directors, employees and agents, arising from or related to the transactions contemplated by this Agreement. Buyer shall not be deemed to be a successor employer with respect to the employment of any employee of Seller
or with respect to any of Seller’s Employee Benefit Plans. Buyer may offer employment to any or all of Seller’s employees and former employees, but shall not be obligated to do so. 
 6.4 Further Assurances. Buyer and Seller shall, and shall cause their respective Affiliates to, at the request and the expense of the other,
execute and deliver such other instruments of conveyance and transfer and assumption and take such other action as may be reasonably requested so as to consummate the transactions contemplated hereby or otherwise to consummate the intent of this
Agreement. Without limiting the generality of the foregoing, the Seller will, and will cause its management to, execute management representation letters reasonably requested by Buyer’s outside auditors in connection with the audit of Seller or
otherwise as is required by applicable securities laws. In addition, prior to or immediately after Closing, Buyer and Seller shall agree on the text of a letter to be sent to present HIV/AIDS patients who are customers of Seller, advising such
patients that their records have been transferred to Buyer. Scott Maiman shall also, during the four (4) month period from the Closing Date through July 13, 2006 provide during normal business hours such reasonable assistance to Buyer as
Buyer from time to time has requested to transition the business of Seller and the Acquired Assets to Buyer, which assistance may be provided by telephone in such cases that physical presence is not necessary to provide such assistance. 

6.5 Prescription Files and Interim Operations. Buyer shall utilize Seller’s provider numbers for Medicare/Medicaid applicable to the
Business for the time period commencing on the Closing Date and ending on the date that Buyer is issued its own Medicare/Medicaid provider numbers; provided, however, that Buyer shall be deemed to have assumed any liability of Seller related thereto
for improper billing by Seller, reimbursement of any overpayments received by Seller for services provided on or before the Closing Date, or any other transactions by Seller under the provider numbers. To the extent permitted by law, Buyer shall be
permitted to bill using Seller’s provider numbers for Medicare/Medicaid until such time as the Buyer is issued its own Medicare/Medicaid number. Seller shall take all commercially reasonable action required to permit Buyer to bill using
Seller’s provider numbers for Medicare/Medicaid. Seller and Buyer understand that reimbursements from Medicare and/or Medicaid for items/services provided/rendered after the Closing Date will continue to be issued to Seller for a period of
time. All such reimbursements that may be received by Seller or over which Seller has control shall be held by Seller, in an account segregated from its other cash assets, for Buyer’s benefit and on its behalf. Seller shall promptly 

 

 16 

 deliver to Buyer any amounts that may be delivered to Seller immediately upon receipt until such time as reimbursements
are remitted directly to Buyer by Medicare and Medicaid. Buyer, in its reasonable discretion, may approve an alternative method of receiving such funds. Furthermore, during that period of time, Seller will promptly deliver to Buyer in electronic
format or such other form mutually agreed to by the parties all Prescription Files that comes into Seller’s possession in accordance with New York State board of pharmacy regulations. 
 6.6 Certain Covenants of Seller. Seller hereby covenants that (unless Buyer otherwise gives its written approval in its sole discretion) Seller
shall at its sole cost and expense take the actions set forth below: 
 (a) At the Closing, Seller shall pay or otherwise discharge all the
Excluded Liabilities in accordance with payment terms of each applicable creditor consistent with previous payment histories. 
 (b) After
the Closing, Seller shall afford Buyer, its attorneys, accountants, consultants and representatives, free and full access to the Acquired Assets and books and records of Seller relating thereto, at all reasonable times upon reasonable notice and
during normal business hours, and shall provide to Buyer and its representatives such additional financial and operating data and other information as Buyer shall from time to time reasonably request. 
 (c) After the Closing, Seller shall use its best efforts to preserve for Buyer the goodwill of its customers and suppliers, and shall do all things
reasonably requested by Buyer for such purpose. 
 (d) After the Closing, Seller shall promptly advise Buyer in writing of the commencement
or threat against Seller of any suit, litigation or legal proceeding that relates to or might affect the Acquired Assets. 
 ARTICLE VII

 RESTRICTIVE COVENANTS 
 7.1 Non-Competition. Seller and Seller’s Shareholders hereby agree that as a material inducement to Buyer to enter into this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, Seller and each of Seller’s Shareholders covenant and agree that it, and each of Seller’s officers, directors and Affiliates, and each of Seller’s Shareholder’s Affiliates and immediate family members, shall
not, for the period from the date hereof until five (5) years following the Closing Date (the “Restricted Period”), directly or indirectly, on its own behalf or in the service of or on the behalf of others, as a director, trustee,
owner (except as the owner of less than two percent (2%) of the outstanding stock of a publicly held corporation), employee, consultant, advisor, independent contractor or in any other capacity, engage in the business of operating a pharmacy
that in any way services or treats, or markets or sells AIDS/HIV products to, AIDS/HIV patients, in any of the five (5) boroughs of New York, or Nassau or Suffolk Counties (the “Restricted Territory”), provided that Scott Maiman shall
be entitled to be employed as a pharmacist at (a) any pharmacy in Nassau or Suffolk Counties whose revenues are less than thirty percent (30%) attributable to AIDS/HIV products and (b) the certain pharmacy at which he is presently
employed on Nostrand Avenue, Brooklyn for a period not to exceed thirty (30) days after the Closing Date. 
  

 17 

 7.2 Non-Interference. Seller and each of Seller’s Shareholders further agree that, during the
Restricted Period and within the Restricted Territory, Seller and each of Seller’s Shareholders will not, directly or indirectly; (i) induce any former customer of or referrer of customers to Seller or customer of or referrer of customers
to Buyer to patronize any Person who competes with Buyer; (ii) request or advise any former customer of or referrer of customers to Seller or customer of or referrer of customers to Buyer to withdraw, curtail or cancel such Person’s
business with Buyer; (iii) enter into any contract, the purpose or result of which would benefit such Seller if any former customer of or referrer of customers to Seller or customer of or referrer of customers to Buyer were to withdraw,
curtail, or cancel such customer’s or referrer’s business with Buyer; or (iv) except as required by law, disclose to any other Person the names or addresses of any former customer of or referrers of customers to Seller or customer of
or referrers of customers to Buyer, either individually or collectively. 
 7.3 Acknowledgements. If the provisions of this Article
VII are violated, in whole or in part, Buyer shall be entitled, upon application to any court of proper jurisdiction, to a temporary restraining order or preliminary injunction to restrain and enjoin Seller and each of Seller’s Shareholders and
Affiliates from such violation without prejudice as to any other remedies Buyer may have at law or in equity. In the event of a violation, Seller and each of Seller’s Shareholders agree that it would be virtually impossible for Buyer to
calculate its monetary damages and that Buyer would be irreparably harmed. If Buyer seeks such temporary restraining order or preliminary injunction, Buyer shall not be required to post any bond with respect thereto, or, if a bond is required, it
may be posted without surety thereon. If any restriction contained in this Article VII is held by any court to be unenforceable, or unreasonable, as to time, geographic area or business limitation, Buyer, Seller and each of Seller’s
Shareholders agree that such provisions shall be and are hereby reformed to the maximum time, geographic area or business limitation permitted by applicable laws. The parties further agree that the remaining restrictions contained in this Article
VII shall be severable and shall remain in effect and shall be enforceable independently of each other. Seller and each of Seller’s Shareholders specifically acknowledge, represent and warrant that the covenants set forth in this Article VII
are reasonable and necessary to protect the legitimate interests of Buyer, and that Buyer would not have entered into this Agreement or paid the Purchase Price in the absence of such covenants. 
 ARTICLE VIII 
 INDEMNIFICATION

 8.1 Survival of Representations and Warranties. All representations and warranties contained in Articles IV and V of this
Agreement shall survive the Closing for the applicable statute of limitations, except that the representations and warranties contained in Sections 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 4.10, 4.20, 4.21 and 4.22 shall survive for only eighteen
(18) months after the Closing Date. 
 8.2 Indemnification by Seller and Seller’s Shareholders. Seller and each of
Seller’s Shareholders shall indemnify and save Buyer and its Affiliates, their respective directors, officers, 
  

 18 

 employees, agents and representatives and all of their successors and assigns (collectively “Buyer Claimants”
and individually a “Buyer Claimant”) harmless from and defend each of them from and against any and all demands, claims, actions, liabilities, losses, costs, damages or expenses whatsoever (including any reasonable attorneys’ fees)
(collectively, “Losses”) asserted against, imposed upon or incurred by Buyer Claimants resulting from or arising out of (a) any inaccuracy or breach of any representation or warranty of Seller and Seller’s Shareholders contained
herein; (b) any breach of any covenant or obligation of Seller contained herein; (c) any liability of Seller arising out of events occurring, conditions existing, products sold or activities of Seller; (d) noncompliance with any
applicable bulk sales or similar laws (including laws which may impose transferee liability on Buyer or an Affiliate of Buyer or create Encumbrances on the Acquired Assets relating to Seller’s liability for sales, use or other taxes or
withholdings arising out of the operations of Seller); and (e) any liability arising out of or related to Seller’s business prior to Closing, or the assertion against a Buyer Claimant of a claim which, if valid, would constitute a
liability arising out of or related to Seller’s business prior to Closing. Notwithstanding the foregoing, in no event shall the aggregate indemnification to be provided by Seller and Seller’s Shareholders solely in respect of matters
referred to in clause (a) above exceed the amount of the Purchase Price. 
 8.3 Indemnification by Buyer. Buyer shall
indemnify and save Seller and its respective Affiliates and their respective directors, officers, employees, agents and representatives (collectively “Seller Claimants” and individually a “Seller Claimant”) harmless from and
defend each of them from and against any and all Losses asserted against, imposed upon or incurred by Seller Claimants resulting from or arising out of (a) any inaccuracy or breach of any representation or warranty of Buyer contained herein;
(b) any breach of any covenant or obligation of Buyer contained herein; and (c) except as described in Section 8.2 above, Buyer’s ownership of the Acquired Assets and operation of its business from and after the Closing Date.

 8.4 Indemnification Procedures. 
 (a) The rights and obligations of each party claiming a right to indemnification hereunder (“Indemnitee”) from the other party (“Indemnitor”) shall be governed by the following rules: 

(i) The Indemnitee shall give prompt written notice to the Indemnitor of any state of facts which Indemnitee determines will give rise to a claim by
the Indemnitee against the Indemnitor based on the indemnity agreements contained herein, stating the nature and basis of said claims and the amount thereof, to the extent known. No failure to give such notice shall affect the indemnification
obligations of Indemnitor hereunder, except to the extent such failure materially prejudices such Indemnitor’s ability successfully to defend the matter giving rise to the indemnification claim. 
 (ii) In the event any action, suit or proceeding is brought against the Indemnitee, with respect to which the Indemnitor may have liability under the
indemnity agreements contained herein, then upon the written acknowledgment by the Indemnitor within thirty days of the bringing of such action, suit or proceeding that it is undertaking and will prosecute the defense of the claim under such
indemnity agreements and confirming that the claim is one with respect to which the Indemnitor is obligated to indemnify and that it will be able to pay 
  

 19 

 the full amount of potential liability in connection with any such claim, the action, suit or proceeding (including all
proceedings on appeal or for review which counsel for the Indemnitee shall deem appropriate) may be defended by the Indemnitor. However, in the event the Indemnitor shall not offer reasonable assurances as to its financial capacity to satisfy any
final judgment or settlement, the Indemnitee may assume the defense and dispose of the claim, after 30 days prior written notice to the Indemnitor. The Indemnitee shall have the right to employ its own counsel in any such case, but the fees and
expenses of such counsel shall be at the Indemnitee’s own expense unless (A) the employment of such counsel and the payment of such fees and expenses both shall have been specifically authorized by the Indemnitor in connection with the
defense of such action, suit or proceeding or (B) the Indemnitee shall have reasonably concluded and specifically notified the Indemnitor that there may be specific defenses available to it which are different from or additional to those
available to the Indemnitor. 
 (iii) In addition, in any event specified in clause (B) of the second sentence of subparagraph
(ii) above, the Indemnitor, to the extent made necessary by such different or additional defenses, shall not have the right to direct the defense of such action, suit or proceeding on behalf of the Indemnitee. If Indemnitor and Indemnitee
cannot agree on a mechanism to separate the defense of matters extending beyond the scope of indemnification, such matters shall be defended on the basis of joint consultation. 
 (iv) The Indemnitee shall be kept fully informed by the Indemnitor of such action, suit or proceeding at all stages thereof, whether or not it is
represented by counsel. The Indemnitor shall, at the Indemnitor’s expense, make available to the Indemnitee and its attorneys and accountants all books and records of the Indemnitor relating to such proceedings or litigation, and the parties
hereto agree to render to each other such assistance as they may reasonably require of each other in order to ensure the proper and adequate defense of any such action, suit or proceeding. 
 (v) The Indemnitor shall make no settlement of any claims which Indemnitor has undertaken to defend, without Indemnitee’s consent, unless the
Indemnitor fully indemnifies the Indemnitee for all losses, there is no finding or admission of violation of law by, or effect on any other claims that may be made against, the Indemnitee and the relief granted in connection therewith requires no
action on the part of and has no effect on the Indemnitee. 
 ARTICLE IX 
 MISCELLANEOUS 
 9.1 Expenses. Each party hereto shall pay its own
expenses incurred in connection with this Agreement, except as otherwise specified in this Agreement and except that all sales, transfer and other similar taxes, levies and charges that may be imposed, levied or assessed in connection with the
consummation of the transactions contemplated hereby shall be borne by Seller. 
 9.2 Amendment. This Agreement may not be terminated,
amended, altered or supplemented except by a written agreement executed by the parties hereto. 
  

 20 

 9.3 Entire Agreement. This Agreement, including the schedules hereto, and the instruments and
other documents delivered pursuant to this Agreement, contain the entire agreement of the parties relating to the subject matter of this Agreement and supersede all other agreements and understandings of any kind between the parties respecting such
subject matter. Each and every representation, warranty and covenant shall be deemed to include the information contained in the schedules thereto. 
 9.4 Waivers. Waiver by either party of either breach of or failure to comply with any provision of this Agreement by the other party shall not be construed as, or constitute, a continuing waiver of such provision, or a waiver of any
other breach of, or failure to comply with, any other provision of this Agreement. No waiver of any such breach or failure or of any term or condition of this Agreement shall be effective unless in a written notice signed by the waiving party and
delivered, in the manner required for notices generally, to each affected party. 
 9.5 Notices. All notices, consents, directions,
approvals, instructions, requests and other communications required or permitted by the terms of this Agreement to be given to any Person shall be in writing, and any such communication shall become effective five Business Days after being deposited
in the United States mails, certified or registered (return receipt requested), with appropriate postage prepaid for first class mail or, if delivered by hand or courier service or in the form of a telex, telecopy or telegram, when received (if
received during normal business hours on a Business Day, or if not, then on the next Business Day thereafter), and shall be directed to the following address or telex or telecopy number: 
  

					
	If to Seller:	  	H.S. Maiman Rx, Inc.
		  	c/o Marc H. Schneider, P.C.
		  	666 Old Country Road
		  	Garden City, New York 11530
		  	Telecopier: 516-393-5556
		
	With a copy to:	  	Marc H. Schneider, P.C.
		  	666 Old Country Road
		  	Garden City, New York 11530
		  	Telecopier: 516-393-5556
		
	If to Buyer:	  	Moms Pharmacy, Inc.
		  	1660 Walt Whitman Road
		  	Melville, New York 11747
		  	Attention: Mr. Mike Moran
		  	Telecopier: 631-249-5863
		
	With a copy to:	  	Nixon Peabody LLP
		  	990 Stewart Avenue
		  	Garden City, New York 11530
		  	Attention:	 	Allan H. Cohen
		  	Telecopier:	 	866-947-2070

  

 21 

 or to such other address as a party may have furnished to the other parties in writing in accordance herewith, except
that notices of change of address shall only be effective upon receipt. Any notice which is so mailed shall be deemed delivered on the fourth Business Day (or Days) after mailing; any notice which is transmitted by telecopier shall be deemed
delivered when transmitted to the telecopier number specified above and acknowledgment of receipt of such facsimile is received. 
 9.6 Counterparts. This Agreement may be executed in two or more counterparts, and by the different parties hereto in separate counterparts each of which when executed shall be deemed to be an original, but all of which together
shall constitute one and the same document. 
 9.7 Governing Law; Submission to Jurisdiction. This Agreement shall be governed
by, and construed in accordance with, the law of the State of New York, without regard to applicable principles of conflict of laws that might otherwise govern. 
 9.8 Binding Effect; Assignment. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns. Neither party shall assign or transfer
this Agreement nor any right or obligation hereunder by operation of law or otherwise without the consent of the other party, except that Buyer may assign its rights under this Agreement to an Affiliate of Buyer. 
 9.9 Severability. If any provision of this Agreement or any part of any such provision is held under any circumstances to be invalid or
unenforceable in any jurisdiction, then: (a) such provision or part thereof shall, with respect to such circumstances and in such jurisdiction, be deemed amended to conform to applicable laws so as to be valid and enforceable to the fullest
possible extent; (b) the invalidity or unenforceability of such provision or part thereof under such circumstances and in such jurisdiction shall not affect the validity or enforceability of such provision or part thereof under any other
circumstances or in any other jurisdiction; and (c) such invalidity or enforceability of such provision or part thereof shall not affect the validity or enforceability of the remainder of such provision or the validity or enforceability of any
other provision of this Agreement. Each provision of this Agreement is separable from every other provision of this Agreement, and each part of each provision of this Agreement is separable from every other part of such provision. 
 9.10 Headings. The headings contained in this Agreement (including the schedules) are for reference purposes only and shall not affect in any
way the meaning or interpretation of this Agreement. 
 9.11 No Agency. Neither party hereto shall be deemed hereunder to be an
agent of, or partner or joint venture with, the other party hereto. 
 9.12 Third Parties. Nothing herein is intended or shall be
construed to confer upon or give to any person other than the parties hereto any rights or remedies under or by reason of this Agreement. 
 9.13 Passage of Title and Risk of Loss. Legal title, equitable title and risk of loss with respect to the Acquired Assets will not pass to Buyer until the Acquired Assets are transferred at the Closing. 
  

 22 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement effective as of the date first above
written. 
  

			
	SELLER:
	
	H.S. MAIMAN RX, INC.
		
	By:	 	  

		 	Scott Maiman
		 	President
	
	SELLER’S SHAREHOLDERS:
	
	  
 SCOTT MAIMAN

	
	  
 NANCY MAIMAN

	
	BUYER:
	
	MOMS PHARMACY OF BROOKLYN, INC.
		
	By:	 	  

		 	Michael Moran
		 	President and Chief Executive Officer

 The undersigned hereby guarantees the complete performance of each of Buyer’s obligations under
Section 8.3 of this Agreement. 
  

			
	ALLION HEALTHCARE, INC.
		
	By:	 	  

		 	Michael Moran
		 	President and Chief Executive Officer

  

 23 

 EXHIBIT A 
 1. Seller has been duly organized and is validly existing and in good standing under the laws of the State of New York. Seller has the power and authority to own, lease and operate its properties and to conduct its
business as it is presently conducted. Seller’s Shareholders are the only shareholders of Seller. 
 2. Seller and each of Seller’s
Shareholders have the power and authority to execute, deliver and perform, and has taken all action necessary to execute, deliver and perform the Agreement. Seller and each of Seller’s Shareholders have duly executed and delivered the
Agreement. 
 3. The Agreement constitutes the valid and binding obligation of Seller and each of Seller’s Shareholders, enforceable
against such Person in accordance with its terms. 
 4. The execution and delivery of the Agreement, and the consummation by Seller and each
of Seller’s Shareholders of the transactions contemplated by the Agreement, do not, with or without the giving of notice or the lapse of time or both, (a) violate (i) the articles of incorporation or bylaws of Seller, (ii) any
Federal or state law or regulation applicable to Seller or Seller’s Shareholders, or (iii) any existing obligation of the Seller or Seller’s Shareholders under any order, writ, judgment or decree of any court or Federal or state
governmental authority, or (b) violate or result in a breach of, constitute a default under, require any consent under, or result in the creation of a lien, charge or encumbrance on any property or assets of the Seller pursuant to, the terms of
any material agreement or instrument to which the Seller or either of Seller’s Shareholders is a party or is bound. 
 5. No
registration, approval, authorization, consent, notice or other action by, or filing with, any Federal or state governmental authority is required on the part of Seller or either of Seller’s Shareholders in connection with the execution and
delivery of the Agreement, or the consummation by Seller or either of Seller’s Shareholders of the transactions contemplated by the Agreement, or if required, such appropriate action has been taken. 
  

 24Amendment No. 1 to Credit Agreement dated August 31, 2005

 Exhibit 4.6.2 
 EXECUTION VERSION 
 FIRST AMENDMENT TO CREDIT AGREEMENT 
 THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of August 31, 2005, is by and among AMEDISYS,
INC., a Delaware corporation (the “Borrower”), those Domestic Subsidiaries of the Borrower identified as a “Guarantor” on the signature pages hereto (individually a “Guarantor” and collectively the
“Guarantors”), the Lenders (defined below) party hereto and WACHOVIA BANK, NATIONAL ASSOCIATION, as administrative agent under the Credit Agreement (defined below) (in such capacity, the “Administrative
Agent”). 
 WITNESSETH 
 WHEREAS, the Borrower, the Guarantors, certain banks and financial institutions from time to time party thereto (the “Lenders”) and the Administrative Agent are parties to that certain Credit Agreement dated as of
July 11, 2005 (as amended, modified, supplemented, restated or amended and restated from time to time, the “Credit Agreement”; capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed
thereto in the Credit Agreement, as amended hereby); 
 WHEREAS, the Credit Parties have requested certain amendments to the Credit
Agreement as described herein; and 
 WHEREAS, the Required Lenders are willing to make such amendments to the Credit
Agreement, subject to the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the agreements hereinafter set
forth, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows: 
 ARTICLE I 
 AMENDMENTS TO CREDIT AGREEMENT 
 1.1 Amendment to Cover Page. The Cover Page of the Credit Agreement is amended to include UBS Securities, LLC, as Documentation Agent, and
Bank of America, N.A., as Documentation Agent. 
 1.2 Amendment to Definition of Consolidated EBITDA. The proviso at the end of
the definition of “Consolidated EBITDA” in Section 1.1 of the Credit Agreement is hereby deleted in its entirety and replaced with the following: 
 ; provided that, for purposes of determining Consolidated EBITDA for any period prior to the Closing Date, Consolidated EBITDA
of (1) the Acquired Company and its 

 
Subsidiaries for such period shall be the amount set forth on Schedule 1.1-4 and (2) any Person acquired by a Credit Party during such period
shall be determined on a pro forma basis as if such Person was acquired at the beginning of such period. 
 1.3 Amendment to
Definition of Excess Cash Flow. The definition of “Excess Cash Flow” in Section 1.1 of the Credit Agreement is hereby deleted in its entirety and replaced with the following: 
 “Excess Cash Flow” shall mean, with respect to any fiscal year of the Borrower, for the Borrower and its Subsidiaries
on a consolidated basis, an amount equal to (a) Consolidated EBITDA for such period minus (b) Consolidated Capital Expenditures for such period minus (c) Scheduled Funded Debt Payments made during such period
minus (d) Consolidated Interest Expense (excluding any Consolidated Interest Expense associated with intercompany indebtedness) for such period minus (e) amounts paid in cash in respect of federal, state, local and foreign
income taxes of the Borrower and its Subsidiaries with respect to such period minus (f) increases in Consolidated Working Capital plus (g) decreases in Consolidated Working Capital minus (h) optional prepayments
of the Term Loan and of the Revolving Loans (to the extent accompanied by a corresponding reduction of the Revolving Commitments) minus (i) capital expenditures excluded from the determination of Consolidated Capital Expenditures for
such fiscal year pursuant to clause (iii) of the definition thereof. 
 1.4 Amendment to Definition of Permitted
Acquisition. Clause (vii) of the definition of “Permitted Acquisition” in Section 1.1 of the Credit Agreement is hereby deleted in its entirety and replaced with the following: 
 (vii) the aggregate consideration (including without limitation equity consideration, earn outs or deferred compensation or non-competition
arrangements and the amount of Indebtedness and other liabilities assumed by the Credit Parties and their Subsidiaries) paid by the Credit Parties and their Subsidiaries (A) in connection with any individual acquisition shall not exceed
$25,000,000 and (B) for all acquisitions made during the term of this Credit Agreement (other than the NCARE Acquisition and the SpectraCare Acquisition) shall not exceed $60,000,000. 
 1.5 Amendment to Definition of Fixed Charge Coverage Ratio. The definition of “Fixed Charge Coverage Ratio” in
Section 1.1 of the Credit Agreement is hereby deleted in its entirety and replaced with the following: 
 “Fixed Charge Coverage Ratio” shall mean, with respect to the Borrower and its Subsidiaries on a consolidated basis for the twelve-month period ending on the last day of any fiscal quarter of the Borrower, the ratio of
(i) Consolidated EBITDA for such period minus Pro Forma Acquisition EBITDA for such period minus Consolidated Capital Expenditures for such period minus total federal, state, local and foreign income, value added and
similar taxes paid or payable in cash during such period plus Consolidated Rent Expense for such period, to (ii) the sum of Consolidated Interest Expense for such 

  

 2 

 
period plus Scheduled Funded Debt Payments for such period plus Restricted Payments made during such period plus Consolidated Rent
Expense for such period. Notwithstanding the foregoing, for purposes of calculating the Fixed Charge Coverage Ration for the fiscal quarters ending September 30, 2005, December 31, 2005 and March 31, 2006, the Fixed Charge
Coverage Ratio shall be determined by annualizing the components thereof during such fiscal quarters such that (i) for the calculation of the Fixed Charge Coverage Ratio as of September 30, 2005, the components of the Fixed Charge Coverage
Ratio for the fiscal quarter ending September 30, 2005 would be multiplied by four (4), (ii) for the calculation of the Fixed Charge Coverage Ratio as of December 31, 2005, the components of the Fixed Charge Coverage Ratio for the two
fiscal quarter period then ending would be multiplied by two (2) and (iii) for the calculation of the Fixed Charge Coverage Ratio as of March 31, 2006, the components of the Fixed Charge Coverage Ratio for the three fiscal quarter
period then ending would be multiplied by one and one-third (1 1/3). 
 1.6 New Definitions. The following definitions are
hereby added to Section 1.1 of the Credit Agreement in the appropriate alphabetical order: 
 “NCARE
Acquisition” shall mean the acquisition by the Borrower of NCARE, Inc., a Virginia corporation, pursuant to that certain Asset Purchase Agreement, dated as of August 1, 2005, between Amedisys Home Health, Inc., of Virginia and NCARE,
Inc., as amended, modified or supplemented from time to time. 
 “SpectraCare Acquisition” shall mean
the acquisition by the Borrower of SpectraCare Home Health Services, Inc., a Kentucky corporation, and its Subsidiaries pursuant to that certain Asset Purchase Agreement, dated as of August [1], 2005, among Amedisys SP-KY, L.L.C., Amedisys SP-TN,
L.L.C., Amedisys SP-IN, L.L.C., Amedisys SP-OH, L.L.C. and SpectraCare Home Health Services, Inc. and its Subsidiaries and equityholders, as amended, modified or supplemented from time to time. 
 ARTICLE II 
 CONDITIONS TO
EFFECTIVENESS 
 2.1 Closing Conditions. 
 This Amendment shall become effective as of the date hereof (the “First Amendment Effective Date”) upon satisfaction of the following conditions (in form and substance reasonably acceptable to the
Administrative Agent): 
 (a) Executed Amendment. The Administrative Agent shall have received a copy of this Amendment
duly executed by each of the Credit Parties and the Required Lenders. 
  

 3 

 (b) Other. The Administrative Agent shall have received such other documents,
agreements or information which it may reasonably request relating to the Credit Parties and the transactions contemplated by this Amendment and any other matters relevant hereto or thereto, all in form and substance satisfactory to the
Administrative Agent in its sole good faith discretion. 
 ARTICLE III 
 MISCELLANEOUS 
 3.1 Amended Terms. All references to the
Credit Agreement in each of the Credit Documents shall hereafter mean the Credit Agreement as amended by this Amendment. Except as specifically amended hereby or otherwise agreed, the Credit Agreement is hereby ratified and confirmed and shall
remain in full force and effect according to its terms. 
 3.2 Representations and Warranties of Credit Parties. Each of
the Credit Parties represents and warrants as follows as of the date hereof, after giving effect to this Amendment: 
 (a) It
has taken all necessary action to authorize the execution, delivery and performance of this Amendment. 
 (b) This Amendment
has been duly executed and delivered by such Person and constitutes such Person’s valid and legally binding obligations, enforceable in accordance with its terms, except as such enforceability may be subject to (i) bankruptcy, insolvency,
reorganization, fraudulent conveyance or transfer, moratorium or similar laws affecting creditors’ rights generally and (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding at law or in
equity). 
 (c) No consent, approval, authorization or order of, or filing, registration or qualification with, any
Governmental Authority or third party is required in connection with the execution, delivery or performance by such Person of this Amendment. 
 (d) The representations and warranties set forth in Article III of the Credit Agreement are true and correct as of the date hereof (except for those which expressly relate to an earlier date). 
 3.3 Acknowledgment of Guarantors. The Guarantors acknowledge and consent to all of the terms and conditions of this Amendment and
agree that this Amendment and all documents executed in connection herewith do not operate to reduce or discharge the Guarantors’ obligations under the Credit Documents. 
 3.4 Credit Document. This Amendment shall constitute a Credit Document under the terms of the Credit Agreement. 
  

 4 

 3.5 Entirety. This Amendment and the other Credit Documents embody the entire
agreement among the parties hereto and supersede all prior agreements and understandings, oral or written, if any, relating to the subject matter hereof. 
 3.6 Counterparts; Telecopy. This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be an original, but all of which shall constitute one
and the same instrument. Delivery of an executed counterpart to this Amendment by telecopy shall be effective as an original and shall constitute a representation that an original will be delivered. 
 3.7 General Release. In consideration of the Required Lenders entering into this Amendment, the Credit Parties hereby release each of the
Administrative Agent, the Lenders, and the Administrative Agent’s and the Lenders’ respective officers, employees, representatives, agents, counsel and directors from any and all actions, causes of action, claims, demands, damages and
liabilities of whatever kind or nature, in law or in equity, now known or unknown, suspected or unsuspected to the extent that any of the foregoing arises from any action or failure to act under the Credit Documents on or prior to the date hereof,
except, with respect to any such Person being released hereby, any actions, causes of action, claims, demands, damages and liabilities arising out of such Person’s gross negligence or willful misconduct. 
 3.8 GOVERNING LAW. THIS AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED AND
INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF (OTHER THAN SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW). 
 3.9 Consent to Jurisdiction and Service of Process; Waivers of Jury Trial and Consequential Damages. The jurisdiction, service of process
and waivers of jury trial and consequential damages provisions set forth in Sections 9.14 and 9.17 of the Credit Agreement are hereby incorporated by reference, mutatis mutandis. 
 3.10 Fees. The Borrower agrees to pay all fees and expenses of the Administrative Agent in connection with the preparation, execution and
delivery of this Amendment, including, without limitation, the fees and expenses of Moore & Van Allen PLLC. 
 [remainder of page
intentionally left blank] 
  

 5 

 IN WITNESS WHEREOF the Borrower, the Guarantors and the Required Lenders have caused this Amendment to be
duly executed on the date first above written. 
  

									
	 BORROWER:
	 		 	 AMEDISYS, INC.,

		 		 	 a Delaware corporation

					
		 		 		 	 By:
	 	 /s/ Gregory H. Browne

		 		 		 	 Name:
	 	 Gregory H. Browne

		 		 		 	 Title:
	 	 Chief Financial Officer

 GUARANTORS: 
  

									
		 		 	 AMEDISYS HOME HEALTH, INC. OF ALABAMA

		 		 	 AMEDISYS HOME HEALTH, INC. OF FLORIDA

		 		 	 AMEDISYS HOME HEALTH, INC. OF SOUTH CAROLINA

		 		 	 AMEDISYS HOME HEALTH, INC. OF VIRGINIA

		 		 	 HOME HEALTH OF ALEXANDRIA, INC.

		 		 	 AMEDISYS LOUISIANA, L.L.C.

		 		 	 AMEDISYS LA ACQUISITIONS, L.L.C.

		 		 	 AMEDISYS PRIVATE DUTY OF GEORGIA, INC.

		 		 	 AMEDISYS, INC.

		 		 	 AMEDISYS GEORGIA, L.L.C.

		 		 	 AMEDISYS NORTHWEST, L.L.C.

		 		 	 AMEDISYS NORTH CAROLINA, L.L.C.

		 		 	 AMEDISYS OKLAHOMA, L.L.C.

		 		 	 AMEDISYS TENNESSEE, L.L.C.

		 		 	 AMEDISYS SPECIALIZED MEDICAL SERVICES, INC.

		 		 	 AMEDISYS QUALITY OKLAHOMA, L.L.C.

		 		 	 AMEDISYS EQUITY GROUP, L.L.C.

		 		 	 AMEDISYS HEALTH MANAGEMENT, L.L.C.

		 		 	 AMEDISYS TEXAS, LTD.

		 		 	 AMEDISYS ARKANSAS, LLC.

		 		 	 AMEDISYS DIABETIC SUPPLY, L.L.C.

		 		 	 AMEDISYS HOSPICE, L.L.C.

		 		 	 AMEDISYS MISSISSIPPI, L.L.C.

		 		 	 AMEDISYS SOUTH FLORIDA, L.L.C.

		 		 	 AMEDISYS SC, L.L.C.

		 		 	 AMEDISYS PROPERTY, LLC.

		 		 	 AMEDISYS MARYLAND, L.L.C.

		 		 	 AMEDISYS HOLDINGS, LLC.

		 		 	 HMR ACQUISITION, INC.

		 		 	 HOUSECALL MEDICAL RESOURCES, INC.

		 		 	 ADVENTA HOSPICE, INC.

		 		 	 HHC, INC.

		 		 	 HOUSECALL HOME HEALTH, INC.

		 		 	 HOUSECALL MEDICAL SERVICES, INC.

		 		 	 HOUSECALL SCS MANAGEMENT, INC.

		 		 	 HOUSECALL SIC MANAGEMENT, INC.

		 		 	 HOUSECALL SUPPORTIVE SERVICES, INC.

		 		 	 HOUSECALL, INC.

					
		 		 		 	 By:
	 	 /s/ Gregory H. Browne

		 		 		 	 Name:
	 	 Gregory H. Browne

		 		 		 	 Title:
	 	 Treasurer

									
	 ADMINISTRATIVE AGENT
	 		 	
	 AND LENDERS:
	 		 	 WACHOVIA BANK, NATIONAL ASSOCIATION,
 as Administrative Agent and as a Lender

					
		 		 		 	 By:
	 	 /s/ Scott Santa Cruz

		 		 		 	 Name:
	 	 Scott Santa Cruz

		 		 		 	 Title:
	 	 Director

			
	 BANK OF AMERICA, N.A.,
 as a
Lender

		
	 By:
	 	 /s/ Alexander L. Rody

	 Name:
	 	 Alexander L. Rody

	 Title:
	 	 Senior Vice President

			
	 GENERAL ELECTRIC CAPITAL CORPORATION,
 as a Lender

		
	 By:
	 	 /s/ Steven Wagablas

	 Name:
	 	 Steven Wagablas

	 Title:
	 	 Duly Authorized Signatory

			
	 UBS LOAN FINANCE, LLC
 as a
Lender

		
	By:	 	 /s/ Wilfred V. Saint

	 Name:
	 	 Wilfred V. Saint

	 Title:
	 	 Director, Banking Products Services, US

		
	 By:
	 	 /s/ Richard L. Tavrow

	 Name:
	 	 Richard L. Tavrow

	 Title:
	 	 Director, Banking Products Services, US

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]